SelCure vs. Lineage: Is There an Off-Balance-Sheet Asset Here, or Just Hard-to-Monetize Optionality?
The Roche collaboration gives SelCure headline economics that can look large relative to Hadassit Bio's size, but the company still carries its 5.07% stake at zero because the Lineage transfer, the missing contract detail, the sealed expert report, and the remaining legal path still block measurement and monetization. For now, SelCure looks more like a litigation-backed option with economic upside than a hidden asset that can already be priced cleanly.
It Looks Like A Hidden Asset, But Only From A Distance
The main article already argued that Hadassit Bio now trades more like a shell with a short cash runway and a legal option than like a life-sciences holding company. This follow-up isolates the only place in the filing where value might still exist beyond the cash balance, SelCure.
At first glance, it is easy to see why this thread is tempting. Around OpRegen, the filing describes economics that can look very large relative to Hadassit Bio's own size, a USD 50 million upfront payment, up to USD 620 million of milestones, and double-digit royalties. At the same time, it describes an agreement between SelCure and Lineage under which all or part of those rights were transferred to the controller for only about USD 31.7 million. That is exactly the sort of gap that creates the phrase "off-balance-sheet asset."
The problem is that Hadassit Bio does not treat it that way in its own financial statements. The company says it still lacks full information on the agreement terms, the allocation of cash, the royalty rate, and even the identity of the party that received or is entitled to the upfront payment and the future proceeds. That is why it continues to carry the SelCure position at zero. That is the heart of the issue. Economically, there may be something here. In accounting and monetization terms, it is still not an asset the company can measure or capture.
| Layer | What is actually disclosed | Why it matters |
|---|---|---|
| Roche economics | USD 50 million upfront, up to USD 620 million of milestones, and double-digit royalties on net OpRegen sales | This is why the company argues that meaningful value was created around SelCure |
| The Lineage agreement | All or part of those rights were transferred to Lineage for about USD 31.7 million | This is where the gap opens between the headline economics and what may have remained in SelCure |
| Hadassit Bio's look-through | 5.07% of SelCure's share capital, about 5.05% on a diluted basis | Even if value exists, it sits behind a small minority position rather than directly on Hadassit Bio's books |
| Accounting treatment | As of December 31, 2025 the SelCure investment is carried at NIS 0, with no movement during the reported periods | Management itself is not claiming that it has a measurable booked asset |
| Legal status | A court-appointed expert report was filed on June 24, 2025 and remained sealed, and the document-discovery proceeding was deleted on March 12, 2026 at the company's request | The case has moved, but it still has not produced a disclosed cash remedy or a public valuation anchor |
This chart does not prove that Hadassit Bio is entitled to any of those sums. What it does show is why the dispute is not merely technical. When the headline economics include a large upfront payment, large milestone potential, and royalties, while the company says SelCure effectively accepted about USD 31.7 million from Lineage, it becomes clear why the dispute is framed as value potentially being pulled away from the minority.
Where The Economic Gap Comes From
Hadassit Bio did not receive this position for free. As part of the July 2017 sale of its SelCure holdings to Lineage Cell Therapeutics, it received an option over SelCure ordinary shares, plus an additional right to participate in 5% of any future financing for five years. During 2022 the company exercised, in stages, all 24,566 options and received 24,447 ordinary shares in SelCure for additional exercise consideration of about USD 992 thousand, equal to NIS 3.452 million. By the end of 2025 it held, to the best of its knowledge, 5.07% of SelCure's share capital and about 5.05% on a diluted basis.
From there, the analysis has to separate three different value layers. The first is the headline scale of the Roche agreement. The second is what remained, if anything, inside SelCure after the intercompany agreement with Lineage. The third is what a 5.07% minority stake can realistically capture from that. Those three layers are not the same, and the filing repeatedly stresses that the company still does not hold the information required to bridge them.
The table below is a mechanical illustration only based on disclosed figures. It is not a claim that Hadassit Bio is entitled to these amounts:
| Item | Disclosed amount | Mechanical 5.07% look-through |
|---|---|---|
| Roche upfront payment | USD 50.0 million | about USD 2.5 million |
| Maximum milestone pool | up to USD 620.0 million | up to about USD 31.4 million |
| Consideration SelCure was supposed to receive from Lineage | about USD 31.7 million | about USD 1.6 million |
What this illustration does show is why SelCure still matters, even at a zero carrying value. If the company's aggressive reading is right, and the rights diverted from SelCure were economically closer to the Roche headline than to the USD 31.7 million figure, then the gap could be material. If, on the other hand, the Lineage agreement was fair, then the value left for minority holders is much smaller. That is the dispute in one sentence.
Why The Position Still Sits At Zero
The accounting note is blunter than the legal language. The company says explicitly that it has not received full information on the cooperation agreement, the milestone terms, the split of cash between Lineage and SelCure, the royalty rate, or even the identity of the party that received or will receive the upfront payment and the future proceeds. In other words, the company knows there was a large economic event, but it still cannot map the cash path with enough confidence.
That is why the accounting treatment remains extremely conservative. Already in the 2021 statements the company assessed SelCure's share value as very low and concluded that the options were out of the money. On March 24, 2022, after a partial exercise notice, it received an indication from SelCure's board that the share value was materially below the option exercise price. Even in the 2025 report, after the legal process, the expert opinion, and the mediation effort, the company still says no new information has been received that would support a higher value, so the fair value remains close to zero, with no movement in the carrying amount during the reported periods.
That matters. Zero carrying value here is not proof that there is no economic dispute. It is proof that the company still does not have the chain of information required to translate the dispute into a measurable asset. Anyone calling SelCure a hidden asset needs to explain first how the Roche headline becomes an actual, measurable right on Hadassit Bio's side of the ledger.
The filing also contains ammunition for the more aggressive view. The company points to an EY valuation dated March 23, 2022 that placed SelCure's equity value at about USD 90 million, and argues that SelCure should be worth materially more today because the drug has progressed further and additional Roche money was likely received. But that too needs to be framed correctly. It is important litigation support. It is not booked value.
The Expert Opinion Advanced The Case, Not The Cash
On June 19, 2024 the court appointed an expert to determine whether the consideration under the Lineage agreement was fair. On June 24, 2025 that expert filed an opinion that included her own valuation work, but the filing says it was sealed because the process was being conducted behind closed doors. The court then asked the parties to update it by September 7, 2025 on whether a settlement had been reached. The parties moved into mediation in August 2025, and two mediation meetings in November and December 2025 ended without meaningful progress.
That is meaningful progress, but not the kind the market can price cleanly yet. As long as the opinion remains sealed, outside investors have no way to know whether it supports a large fairness gap, a narrower one, or the fairness of the Lineage consideration. So the existence of a court expert adds weight to the dispute, but still does not create a public valuation anchor.
The post-balance-sheet development leaves the story in an in-between state as well. On January 14, 2026 the company asked to end the document-discovery process because, in its view, that route had exhausted itself, and to renew the legal effort through a more suitable proceeding in light of the expert's conclusions. On March 12, 2026 the court allowed the company to terminate the process and deleted the proceeding. As of the report date, the company says it is considering its next steps and the possibility of publishing the expert report or at least its conclusions.
The analytical takeaway is that the legal story did not die, but it also did not mature into cash. The first process ended without a settlement and without disclosed conclusions, and the next legal route had still not taken public shape. That is why the post-balance-sheet note does not turn SelCure into an accessible asset. It only shows that the company is still trying to create a path to realization.
Why The Optionality Is Hard To Monetize Even If The Company Is Right
The first constraint is structural. Even if it eventually turns out that Lineage captured an unfair share of the OpRegen economics, value would first have to return to, or be recognized within, SelCure, and only then flow, directly or indirectly, to a 5.07% minority holder. This is not a direct right against Roche. It is an economic claim that has to travel through the held company first.
The second constraint is information. To this day, the company says it still lacks full visibility on who received the upfront payment, who is entitled to the milestones, and how royalties are allocated. So even investors who believe there is a real economic wrong here still cannot build a clean bridge from the headline numbers to value for Hadassit Bio shareholders.
The third constraint is procedural. The expert opinion already exists, but the proceeding that produced it has now been deleted, and the next appropriate legal route is still only being examined. In other words, even if the company believes the expert has strengthened its case, there is still a gap between legal ammunition and an enforceable judgment, settlement, or cash flow.
The fourth constraint is cash-capture friction. The USD 350 thousand shareholder loan received on December 1, 2025 matures after 14 months or within 7 business days after the company receives proceeds in an amount equal to the loan from the SelCure proceeding, whichever comes first. So even if a qualifying receipt is eventually obtained, part of the initial cash may first shorten the bridge rather than immediately expand free liquidity.
| Step from dispute to value | What has to happen | What is still missing |
|---|---|---|
| Establish the economic gap | Clarify whether the USD 31.7 million consideration was fair | The expert opinion is still sealed and its conclusions are undisclosed |
| Convert that into a legal remedy | Launch the right substantive proceeding or reach an enforceable settlement | The discovery route has been deleted, and the next route is still under review |
| Convert that into SelCure value | Show what rights and cash stayed in, or return to, SelCure | There is still no full disclosure on the upfront payment, milestones, and royalties |
| Convert that into Hadassit Bio value | Show what actually reaches a 5.07% minority holder | A qualifying recovery could first shorten the bridge loan, and the whole path still depends on the legal outcome |
Conclusion
SelCure is not noise. The filing describes a real economic dispute around an asset that could be very large at the far end of the tree, and the court has already appointed an expert who delivered a valuation-based opinion. But that still falls short of an off-balance-sheet asset in the practical, accessible sense.
The more precise label, as of year-end 2025 and March 12, 2026, is litigation-backed optionality with economic upside, but with a difficult path to realization. The Roche headline explains why the option is alive. The Lineage agreement explains why the company says value may have been stripped away. The zero carrying value, the sealed expert report, and the still-unformed substantive legal path explain why the market still cannot read this as an accessible asset.
Current thesis: SelCure currently looks more like an option on legal progress and forced disclosure than like a hidden asset from which value can already be extracted for shareholders.
What changes that reading is not another forceful company statement. It is three harder things: some disclosure of the expert's conclusions, a substantive legal route aimed at a real economic remedy, and a clearer cash path showing who received what and what could actually end up in SelCure and then in Hadassit Bio.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.